Witnessing the stock’s movement on the chart, on Thursday, Candel Therapeutics Inc (NASDAQ: CADL) set off with pace as it heaved 3.36% to $4.62, before settling in for the price of $4.47 at the close. Taking a more long-term approach, CADL posted a 52-week range of $4.25-$14.60.
The Healthcare sector firm’s twelve-monthly sales growth has been -43.86% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -43.86%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 73.16%. This publicly-traded company’s shares outstanding now amounts to $54.90 million, simultaneously with a float of $41.06 million. The organization now has a market capitalization sitting at $253.63 million. At the time of writing, stock’s 50-day Moving Average stood at $5.26, while the 200-day Moving Average is $5.94.
Candel Therapeutics Inc (CADL) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Candel Therapeutics Inc’s current insider ownership accounts for 25.21%, in contrast to 41.42% institutional ownership. According to the most recent insider trade that took place on Jul 28 ’25, this organization’s Chief Medical Officer sold 937 shares at the rate of 6.98, making the entire transaction reach 6,540 in total value, affecting insider ownership by 52,493. Preceding that transaction, on Jun 30 ’25, Company’s Chief Medical Officer sold 781 for 5.04, making the whole transaction’s value amount to 3,936. This particular insider is now the holder of 52,493 in total.
Candel Therapeutics Inc (CADL) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year. Candel Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 73.16% and is forecasted to reach -0.99 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 35.44% through the next 5 years, which can be compared against the -43.86% growth it accomplished over the previous five years trading on the market.
Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators
In the same vein, CADL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.56, a figure that is expected to reach -0.25 in the next quarter, and analysts are predicting that it will be -0.99 at the market close of one year from today.
Technical Analysis of Candel Therapeutics Inc (CADL)
Going through the that latest performance of [Candel Therapeutics Inc, CADL]. Its last 5-days volume of 0.76 million was inferior to the volume of 0.96 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 27.79% While, its Average True Range was 41.98.
Raw Stochastic average of Candel Therapeutics Inc (CADL) in the period of the previous 100 days is set at 9.31%, which indicates a major fall in contrast to 27.84% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.28 that was lower than 0.34 volatility it exhibited in the past 100-days period.
